Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vir Biotechnology (VIR)

Vir Biotechnology's Chief Medical Officer Mark Eisner to step down April 24, 2026

Neutral Impact 4 of 5 leadership Written later

Vir Biotechnology said its Executive Vice President and Chief Medical Officer, Mark Eisner, informed the company on April 7, 2026 that he will step down effective April 24, 2026. The company has started searching for a successor, and the filing does not name an interim replacement.

Key points

  • Mark Eisner, EVP and Chief Medical Officer, will step down effective April 24, 2026.
  • He informed the company of his decision on April 7, 2026.
  • Vir has initiated a search for his successor.

The filing

CompanyVir Biotechnology (VIR)
Form8-K, current report
Filed with the SECApr 10, 2026, 4:01 PM ET
Accession number0001193125-26-151209

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.